Last reviewed · How we verify
COVID-19 convalescent hyperimmune plasma
COVID-19 convalescent hyperimmune plasma works by transferring antibodies from recovered COVID-19 patients to help the body fight the virus.
COVID-19 convalescent hyperimmune plasma works by transferring antibodies from recovered COVID-19 patients to help the body fight the virus. Used for Treatment of severe COVID-19.
At a glance
| Generic name | COVID-19 convalescent hyperimmune plasma |
|---|---|
| Sponsor | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
This treatment involves infusing plasma from individuals who have recovered from COVID-19, which contains antibodies that can help neutralize the virus. These antibodies can provide immediate protection to patients who are severely ill or at high risk of developing severe disease.
Approved indications
- Treatment of severe COVID-19
Common side effects
- Thrombosis
- Allergic reactions
Key clinical trials
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Convalescent Plasma in Hospitalized COVID-19 Patients
- Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients (PHASE2, PHASE3)
- Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection (PHASE1, PHASE2)
- Early Use of Hyperimmune Plasma in COVID-19 (NA)
- Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial (PHASE2)
- plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients (PHASE2)
- Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: